BIOPHARMA CREDIT PLC
Notification of Transactions by
Persons Discharging Managerial Responsibilities and
Persons Closely Associated with them
|
1. |
Details of person discharging managerial responsibilities/person closely associated with them |
||||||
|
a) |
Name |
Anita Hyman |
|||||
|
2. |
Reason for the notification |
||||||
|
a) |
Position / status |
Person Closely Associated with Harry Hyman (Director of BioPharma Credit PLC) |
|||||
|
b) |
Initial notification / amendment |
Initial notification |
|||||
|
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||
|
a) |
Name |
BioPharma Credit PLC |
|||||
|
b) |
LEI |
213800AV55PYXAS7SY24 |
|||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||
|
a) |
Description of the financial instrument
Identification Code |
Ordinary Shares of $0.01 each
GB00BDGKMY29 |
|||||
|
b) |
Nature of the transaction |
Purchase of Shares (acquired as part of dividend reinvestment) |
|||||
|
c) |
Price(s) and volume(s) |
|
|||||
|
d) |
Aggregated information - Aggregated volume
- Price |
N/A
|
|||||
|
e) |
Date of the transaction |
30.10.2024 |
|||||
|
f) |
Place of the transaction |
London Stock Exchange (XLON) |
|||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
